AJP - Renal Physiology, Vol 248, Issue 6 753-F756, Copyright © 1985 by American Physiological Society
Effects of selective inhibition of thromboxane synthesis on renal function in humans
R. D. Zipser
Thromboxane A2, a potent vasoconstrictor, is a major metabolite of
arachidonic acid in the human kidney. To determine the role of thromboxanes
in renal hemodynamics, we administered the new thromboxane inhibitor
dazmegrel or placebo to 20 healthy volunteers for 14 days in a double-blind
protocol. Dazmegrel reduced urinary thromboxane B2 by an average of 68% and
serum thromboxane B2 by 79%, without affecting urinary excretion of the
prostacyclin metabolite 6-ketoprostaglandin F 1 alpha. Neither
p-aminohippurate clearance nor inulin clearance were altered by thromboxane
inhibition. Thus it is unlikely that thromboxane A2 plays a major role in
the regulation of glomerular function in healthy humans.
